MacroGenics, Inc.
MGNX
Rank in Stocks
#17960
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers,... MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The companyโs product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Share Price
$2.34
Last synced: 2026-11-09
Market Cap
$149.06M
Change (1 day)
0.43%
Change (1 year)
59.18%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade MacroGenics, Inc. (MGNX)
Category
Healthcare
Operating Margin for MacroGenics, Inc. (MGNX)
Operating Margin as of November 2026 TTM: -24.30%
According to MacroGenics, Inc.'s latest financial reports, its current operating margin (TTM) is -24.30%. At the end of 2025 the company had an operating margin of -48.72%.
Operating Margin history for MacroGenics, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -24.30% | -50.12% |
| 2025 | -48.72% | -34.64% |
| 2024 | -74.54% | -74.66% |
| 2023 | -294.17% | 263.44% |
| 2022 | -80.94% | -69.81% |
| 2021 | -268.09% | 99.98% |
| 2020 | -134.06% | -53.07% |
| 2019 | -285.67% | 0.32% |
| 2018 | -284.77% | 1,899.79% |
| 2017 | -14.24% | -79.47% |
| 2016 | -69.35% | 246.58% |
| 2015 | -20.01% | -75.32% |
| 2014 | -81.07% | -12,767.19% |
| 2013 | 0.64% | -95.35% |
| 2012 | 13.76% | 23.30% |
| 2011 | 11.16% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.59% |
US
|
|
| -149.01% | -93.87% |
US
|
|
| 25.57% | -101.05% |
AU
|
|
| 31.23% | -101.29% |
BE
|
|
| 29.35% | -101.21% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MacroGenics, Inc.'s operating margin
What is MacroGenics, Inc.'s operating margin?
MacroGenics, Inc.'s operating margin is -24.30%, as of Nov 2026.
What was MacroGenics, Inc.'s operating margin in 2025?
In 2025, MacroGenics, Inc.'s operating margin was -48.72%, compared with -74.54% in 2024.
How has MacroGenics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, MacroGenics, Inc.'s operating margin was highest in 2025 (-48.72%) and lowest in 2023 (-294.17%).
How does MacroGenics, Inc.'s operating margin compare with similar companies?
MacroGenics, Inc.'s operating margin (-24.30%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.